NCT04263831View on ClinicalTrials.gov

Low Dose IL-2 for the Treatment of Crohn's Disease

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 11, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Crohn Disease
Interventions
DRUG

Interleukin-2 (aldesleukin).

"Description of intervention is covered in Arm, above."

Trial Locations (3)

10029

RECRUITING

Mount Sinai, New York

02115

RECRUITING

Boston Children's Hospital, Boston

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Boston Children's Hospital

OTHER